CA2230690C - Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments - Google Patents
Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments Download PDFInfo
- Publication number
- CA2230690C CA2230690C CA002230690A CA2230690A CA2230690C CA 2230690 C CA2230690 C CA 2230690C CA 002230690 A CA002230690 A CA 002230690A CA 2230690 A CA2230690 A CA 2230690A CA 2230690 C CA2230690 C CA 2230690C
- Authority
- CA
- Canada
- Prior art keywords
- pain
- ketamine
- administration
- transmucosal
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 title claims abstract description 177
- 229960003299 ketamine Drugs 0.000 title claims abstract description 171
- 208000002193 Pain Diseases 0.000 title claims abstract description 158
- 230000036407 pain Effects 0.000 title claims abstract description 141
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 229940079593 drug Drugs 0.000 title abstract description 54
- 208000000003 Breakthrough pain Diseases 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 230000037396 body weight Effects 0.000 claims description 18
- 208000000094 Chronic Pain Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 206010013954 Dysphoria Diseases 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 238000012385 systemic delivery Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000004081 narcotic agent Substances 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 17
- 238000002560 therapeutic procedure Methods 0.000 abstract description 16
- 230000009467 reduction Effects 0.000 abstract description 11
- 235000009508 confectionery Nutrition 0.000 abstract description 8
- 239000000829 suppository Substances 0.000 abstract description 8
- 206010005063 Bladder pain Diseases 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 229940124583 pain medication Drugs 0.000 description 21
- 238000007726 management method Methods 0.000 description 17
- 230000008901 benefit Effects 0.000 description 13
- 230000003533 narcotic effect Effects 0.000 description 11
- 230000000202 analgesic effect Effects 0.000 description 10
- 229940035676 analgesics Drugs 0.000 description 9
- 239000000730 antalgic agent Substances 0.000 description 9
- 210000004877 mucosa Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010028813 Nausea Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000008693 nausea Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 239000003961 penetration enhancing agent Substances 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 239000000932 sedative agent Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000009429 distress Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000004084 narcotic analgesic agent Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 208000004404 Intractable Pain Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 229940127450 Opioid Agonists Drugs 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 231100000223 dermal penetration Toxicity 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 229940039412 ketalar Drugs 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- -1 nasal Chemical compound 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 208000037974 severe injury Diseases 0.000 description 2
- 230000009528 severe injury Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- 229920002507 Poloxamer 124 Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 241001074085 Scophthalmus aquosus Species 0.000 description 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009232 chiropractic Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- QJHCNBWLPSXHBL-UHFFFAOYSA-N cimetidine hydrochloride Chemical compound [H+].[Cl-].N#C/N=C(/NC)NCCSCC=1N=CNC=1C QJHCNBWLPSXHBL-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940088505 compazine Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940116314 ketaject Drugs 0.000 description 1
- 229940015418 ketaset Drugs 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 229940062711 laureth-9 Drugs 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 208000018731 motor weakness Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940124637 non-opioid analgesic drug Drugs 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229940093448 poloxamer 124 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940106721 tagamet Drugs 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Procédé de gestion de la douleur qui ne nécessite pas l'administration de narcotiques ou en permet la réduction, et de gestion personnelle de la douleur sur la base de consultations externes. La présente invention concerne donc, de manière générale, un procédé de traitement de la douleur chez un sujet, qui consiste à administrer à travers les muqueuses, par voie percutanée ou orale une dose de kétamine efficace pour soulager la douleur chez un sujet qui y est en proie. Le présente invention concerne en outre un procédé de traitement synergique de la douleur chez un sujet, qui consiste à administrer, par une voie quelconque, une dose de kétamine efficace pour permettre la réduction des substances administrées dans le cadre de la thérapie de lutte contre la douleur en cours, ou pour réduire la douleur (améliorer le niveau de soulagement de la douleur), ou les deux. L'administration par les muqueuses, percutanée ou orale de kétamine permet avantageusement au patient de s'administrer lui-même le médicament, ce qui conduit à une gestion de la douleur sur la base de consultations externes. De plus, l'administration de kétamine par des dispositifs percutanés (suppositoires, pastilles, timbres buccaux) est en général socialement acceptable. Dans un exemple spécifique, un patient souffrant de douleurs rebelles de la vessie a pu lutter contre l'apparition des douleurs par administration à travers les muqueuses (nasale) d'environ 16 à environ 32 mg de kétamine par dose.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US294695P | 1995-08-30 | 1995-08-30 | |
| US60/002,946 | 1995-08-30 | ||
| PCT/US1996/014095 WO1997007750A1 (fr) | 1995-08-30 | 1996-08-29 | Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2230690A1 CA2230690A1 (fr) | 1997-03-06 |
| CA2230690C true CA2230690C (fr) | 2008-12-23 |
Family
ID=21703322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002230690A Expired - Fee Related CA2230690C (fr) | 1995-08-30 | 1996-08-29 | Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments |
Country Status (3)
| Country | Link |
|---|---|
| JP (2) | JPH11511466A (fr) |
| CA (1) | CA2230690C (fr) |
| WO (1) | WO1997007750A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1103256A1 (fr) * | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique |
| DE10025946A1 (de) * | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Wirkstoffkombination |
| JP2005515966A (ja) | 2001-07-06 | 2005-06-02 | エンドー ファーマシューティカルズ， インコーポレイティド | 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与 |
| DE60223254T2 (de) | 2001-07-06 | 2008-08-14 | Penwest Pharmaceuticals Co. | Verzögert freisetzende formulierungen von oxymorphon |
| US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| JP2006510618A (ja) * | 2002-11-18 | 2006-03-30 | ヤウポン セラピューティクス，インコーポレーテッド | ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 |
| WO2004087209A1 (fr) * | 2003-03-27 | 2004-10-14 | Hisamitsu Pharmaceutical Co., Inc. | Preparation pour assurer une concentration sanguine therapeutiquement efficace d'un potentialisateur d'activite analgesique |
| WO2013056229A1 (fr) | 2011-10-14 | 2013-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilisation de (2r, 6r)-hydroxynorkétamine, (s)-déshydronorkétamine et autres métabolites déshydro et hydroxylés stéréo-isomères de (r,s)-kétamine dans le traitement de la dépression et de la douleur neuropathique |
| US20140079740A1 (en) * | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| CN107847469A (zh) * | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US9963435B2 (en) | 2016-08-31 | 2018-05-08 | Dart Neuroscience, Llc | Compounds for therapeutic use |
| WO2019033330A1 (fr) | 2017-08-17 | 2019-02-21 | Xw Laboratories, Inc. | Préparation et utilisations de dérivés piégeurs d'espèces réactives de l'oxygène |
| EP3679051B1 (fr) | 2017-09-04 | 2021-12-29 | XWPharma Ltd. | Préparation et utilisation d'un piégeur d'espèces réactives de l'oxygène |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| KR20240011237A (ko) | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| PL3737665T3 (pl) * | 2018-01-10 | 2026-04-20 | XWPharma Ltd. | Proleki ketaminy, ich kompozycje i zastosowania |
| JP2022524008A (ja) | 2019-03-05 | 2022-04-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のためのエスケタミン |
| EP3968979A4 (fr) * | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | Formulation de kétamine pour injection sous-cutanée |
| JP2023511370A (ja) | 2020-01-22 | 2023-03-17 | シーロス セラピューティクス， インコーポレイテッド | Ｎｍｄａ拮抗薬の副作用の低減 |
| EP4559522A3 (fr) | 2021-08-13 | 2025-07-16 | XWPharma Ltd. | Compositions pharmaceutiques et formes posologiques orales de dérivés de kétamine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671953A (en) * | 1985-05-01 | 1987-06-09 | University Of Utah Research Foundation | Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics |
| CA2115792C (fr) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Methode de traitement de la douleur |
| US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
-
1996
- 1996-08-29 CA CA002230690A patent/CA2230690C/fr not_active Expired - Fee Related
- 1996-08-29 WO PCT/US1996/014095 patent/WO1997007750A1/fr not_active Ceased
- 1996-08-29 JP JP9510636A patent/JPH11511466A/ja not_active Withdrawn
-
2008
- 2008-10-01 JP JP2008256699A patent/JP2009073842A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11511466A (ja) | 1999-10-05 |
| WO1997007750A1 (fr) | 1997-03-06 |
| CA2230690A1 (fr) | 1997-03-06 |
| JP2009073842A (ja) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6248789B1 (en) | Administration of ketamine to manage pain and to reduce drug dependency | |
| CA2230690C (fr) | Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments | |
| US5543434A (en) | Nasal administration of ketamine to manage pain | |
| EP1567145B1 (fr) | Utilisations analgesiques de (s)-norketamine | |
| MXPA96003633A (en) | Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification | |
| EP1007045B1 (fr) | Application topique de medicaments analgesiques opioides tels que de la morphine | |
| EA006384B1 (ru) | Композиция фентанила для интраназального введения | |
| US5989582A (en) | Administration of ketamine for detoxification and to treat substance addiction, and compositions therefor | |
| KR20050088188A (ko) | 상부 호흡기 충혈 치료용 조성물 및 치료 방법 | |
| KR101971412B1 (ko) | 정맥 내 투여용 이부프로펜의 투여 | |
| US6787149B1 (en) | Topical application of opioid analgesic drugs such as morphine | |
| AU733284B2 (en) | Nasal and ocular administration of ketamine to manage pain and for detoxification | |
| NO309965B1 (no) | Oralt farmasøytisk antihostepreparat | |
| US20080132531A1 (en) | Synergistic combinations of norketamine and opioid analgesics | |
| MILLS et al. | Opioid Side Effects | |
| CA2596947A1 (fr) | Administration nasale et oculaire de ketamine pour le traitement de la douleur et les desintoxications | |
| Exchange | Chemical Formula: C₂H₂, NO4; molecular wt | |
| HK1079461B (en) | Analgesic uses of (s)-norketamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140829 |